Ofev
The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Ofev in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Ofev.
41
Global Revenue Ranking
Recent articles on PMLiVE featuring Ofev
Pulmonary fibrosis, a chronic lung condition, affects up to 20 out of every 100,000 people worldwide
Patients will be eligible for the antifibrotic treatment earlier in the course of their disease
Agency is due to make a decision for the approval by May 2021
Drug was first approved in 2014 for pulmonary fibrosis
Lilly’s migraine med Emgality receives negative opinion for label extension
Agrees to pay up to €1bn for each new marketed product
New company will be headquartered in Copenhagen, Denmark
Portfolio includes phase 2 candidate with FDA breakthrough status
Follows discontinuation of Eisai-partnered Alzheimer’s drug
First drug approved for condition
Comes amid restructuring and bolt-on deals to bolster business
Will focus on developing cancer therapies
Data provided by GlobalData
GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.
Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.
To find out more about how our research and insights can help you, please visit https://www.globaldata.com/who-we-are/why-globaldata/
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology